News | August 08, 2025
Caplin Point Laboratories posts Q1 FY26 consolidated PAT at Rs. 152.80 Cr
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
Caplin Point Laboratories has reported total income of Rs. 533.36 crores during the period ended June 30, 2025
Quest will now offer dialysis-related clinical testing services to independent dialysis clinics
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Revenue increased 11.4 per cent to Rs. 8,545 crore
Granules India receives 1 observation from USFDA for Chantilly facility
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The company expects meaningful revenue contribution from this long-term agreement
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The company has posted net profit of Rs. 260.10 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
